$3.75 Million in Sales Expected for Editas Medicine Inc (EDIT) This Quarter

Share on StockTwits

Equities analysts expect Editas Medicine Inc (NASDAQ:EDIT) to announce sales of $3.75 million for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Editas Medicine’s earnings. The highest sales estimate is $7.00 million and the lowest is $1.80 million. Editas Medicine posted sales of $3.67 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 2.2%. The company is scheduled to issue its next earnings results on Tuesday, March 5th.

On average, analysts expect that Editas Medicine will report full-year sales of $25.13 million for the current financial year, with estimates ranging from $15.00 million to $39.03 million. For the next fiscal year, analysts expect that the business will post sales of $32.29 million, with estimates ranging from $16.30 million to $58.10 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Editas Medicine.

Editas Medicine (NASDAQ:EDIT) last announced its quarterly earnings results on Wednesday, November 7th. The company reported ($0.32) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.72) by $0.40. The company had revenue of $14.52 million for the quarter, compared to analyst estimates of $9.83 million. Editas Medicine had a negative net margin of 410.68% and a negative return on equity of 52.88%. Editas Medicine’s revenue for the quarter was up 131.2% on a year-over-year basis. During the same quarter last year, the business earned ($0.64) EPS.

Several research firms recently weighed in on EDIT. Guggenheim began coverage on shares of Editas Medicine in a report on Tuesday, October 9th. They set a “neutral” rating on the stock. BidaskClub lowered shares of Editas Medicine from a “buy” rating to a “hold” rating in a report on Tuesday, October 2nd. Raymond James began coverage on shares of Editas Medicine in a report on Friday, September 21st. They set an “outperform” rating and a $40.00 target price on the stock. Zacks Investment Research lowered shares of Editas Medicine from a “buy” rating to a “hold” rating in a report on Thursday, August 9th. Finally, JPMorgan Chase & Co. set a $36.00 target price on shares of Editas Medicine and gave the company a “hold” rating in a report on Monday, August 6th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and six have issued a buy rating to the company. Editas Medicine currently has an average rating of “Hold” and an average target price of $46.50.

In related news, CEO Katrine Bosley sold 12,000 shares of Editas Medicine stock in a transaction on Monday, August 20th. The shares were sold at an average price of $30.17, for a total transaction of $362,040.00. Following the sale, the chief executive officer now owns 1,270,399 shares of the company’s stock, valued at approximately $38,327,937.83. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CTO Vickesh Myer sold 3,000 shares of Editas Medicine stock in a transaction on Friday, August 17th. The stock was sold at an average price of $29.65, for a total transaction of $88,950.00. Following the sale, the chief technology officer now directly owns 3,000 shares in the company, valued at approximately $88,950. The disclosure for this sale can be found here. Insiders have sold a total of 86,000 shares of company stock worth $2,601,360 in the last ninety days. 5.20% of the stock is currently owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in the stock. Trexquant Investment LP purchased a new stake in Editas Medicine during the 3rd quarter worth $480,000. BlackRock Inc. increased its stake in Editas Medicine by 3.9% during the 3rd quarter. BlackRock Inc. now owns 3,589,141 shares of the company’s stock worth $114,207,000 after buying an additional 134,075 shares during the period. Bank of New York Mellon Corp increased its stake in Editas Medicine by 2.9% during the 3rd quarter. Bank of New York Mellon Corp now owns 198,851 shares of the company’s stock worth $6,327,000 after buying an additional 5,579 shares during the period. Swiss National Bank increased its stake in Editas Medicine by 4.4% during the 3rd quarter. Swiss National Bank now owns 61,800 shares of the company’s stock worth $1,966,000 after buying an additional 2,600 shares during the period. Finally, ARK Investment Management LLC increased its stake in Editas Medicine by 28.1% during the 3rd quarter. ARK Investment Management LLC now owns 2,793,854 shares of the company’s stock worth $88,900,000 after buying an additional 612,282 shares during the period. 67.31% of the stock is currently owned by hedge funds and other institutional investors.

Shares of EDIT traded down $1.03 during mid-day trading on Monday, reaching $28.95. The company had a trading volume of 706,287 shares, compared to its average volume of 658,997. The firm has a market cap of $1.36 billion, a PE ratio of -9.71 and a beta of 3.14. Editas Medicine has a fifty-two week low of $22.50 and a fifty-two week high of $45.02. The company has a quick ratio of 14.50, a current ratio of 14.50 and a debt-to-equity ratio of 0.14.

Editas Medicine Company Profile

Editas Medicine, Inc operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments.

Read More: Why Dividend Stocks May Be Right for You

Get a free copy of the Zacks research report on Editas Medicine (EDIT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Spindle  and Paypal  Head to Head Analysis
Spindle and Paypal Head to Head Analysis
GlassCoin Price Hits $0.0038 on Major Exchanges
GlassCoin Price Hits $0.0038 on Major Exchanges
Wechter Feldman Wealth Management Inc. Buys 665 Shares of JPMorgan Chase & Co.
Wechter Feldman Wealth Management Inc. Buys 665 Shares of JPMorgan Chase & Co.
Kinder Morgan Inc  Shares Bought by Linscomb & Williams Inc.
Kinder Morgan Inc Shares Bought by Linscomb & Williams Inc.
Gould Asset Management LLC CA Invests $203,000 in Raytheon  Stock
Gould Asset Management LLC CA Invests $203,000 in Raytheon Stock
Vanguard Real Estate ETF  Shares Bought by Lbmc Investment Advisors LLC
Vanguard Real Estate ETF Shares Bought by Lbmc Investment Advisors LLC


Leave a Reply

© 2006-2018 Ticker Report